# Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

> **NCT04481932** · PHASE2 · RECRUITING · sponsor: **Peking University** · enrollment: 104 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab combined with Pyrotinib and chemotherapy

## Key facts

- **NCT ID:** NCT04481932
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07
- **Primary completion:** 2022-06
- **Final completion:** 2026-12
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04481932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04481932, "Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04481932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*